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γmean(19vs37cp)=0.7±0.1, γmean(19vs73cp)=0.6±0.1 and 
γmean(37vs73cp)=0.6±0.1. The cumulated iQM signal 
coincided with 2D ionchamber array measurements and 
demonstrated accurate reproducibility for all three plans 
(figure 1b). The control-point resolved analysis (fig.1c) 
consistently indicated large deviations between 19cp, 37cp 
and 73cp plans due to an imprecise data sampling 
synchronization of the preclinical version of the detector. 
The symmetry of the test plan could not be reflected by the 
iQM system, especially regarding the 19cp plan. 
 
 
 
Conclusion: Increasing the number of control-points changed 
VMAT delivery accuracy marginally. For clinical treatment 
plans this effect might not be noticeable. Observation of the 
cumulative iQM signal coincided well with dosimetric 
measurements. The VMAT benchmark plan proved to be a 
prospective tool for visualizing and understanding linac and 
detector limitations. 
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Purpose or Objective: Plan verification in complex 
treatment delivery techniques such as IMRT and VMAT is 
imperative. Although some studies have been conducted on 
pre-treatment VMAT quality assurance using PTW Octavius 4D 
systems, more works are needed to focus on complex VMAT 
plans including steep gradient regions. The aim of this study 
is to evaluate dose delivery of different VMAT plans such as 
Head and Neck (SIB: Simultaneously Integrated Boost), lung 
(SBRT: Stereotactic Body Radiation Therapy) and prostate 
(Hypo-fractionated intensity modulated arc therapy) with the 
Octavius 4D system. 
 
Material and Methods: Fifteen head and neck, lung and 
prostate VMAT plans for fifteen patients (5 patients for each 
case) were created and their respective QA plans were 
calculated. All plans were optimized and calculated using 
Monaco (version 5.0) treatment planning system, which is a 
Monte Carlo-based treatment planning system. The 2D-array 
seven29, which consists of 729 vented plane-parallel 
ionization chambers arranged in a 27 x 27 matrix with the 
spatial resolution of 10mm, embedded in Octavius 4D 
cylindrical phantom was used to measure the dose 
distribution and the measurements were done with an Elekta 
Synergy linear accelerator equipped with an Agility 160 MLC 
system. In order to reconstruct and analyze the measured 3D 
dose from each plan, the PTW VeriSoft patient plan 
verification software was used and a volumetric 3D gamma 
index analysis for both 3%/3mm and 2%/2mm criteria was 
performed to compare and evaluate the measured and 
calculated doses. In addition, in order to improve the spatial 
resolution in cranial caudal direction due to 1 cm gap across 
the chambers the second measure was done by shifting the 
array 5 mm (via couch shift) in caudal direction and merging 
the matrices with the “merge” function available in PTW 
VeriSoft. 
 
Results: The mean pass rate of volumetric 3D gamma index 
for all prostate cases was superior to 97% with 3%/3mm and 
92% with 2%/2mm criteria. However, the mean passing rate 
for lungs was lower than prostate and ranged from 93.7 to 
96.3 (3%/3mm) and from 90 to 94.1 (2%/2mm). Expectedly, 
the mean value of global gamma index for head and neck 
cases could not be better than 91.5% (ranged from 88.4 to 
96.3) and 87.3% (ranged from 82.3 to 89) for the 3%/3mm and 
2%/2mm criteria respectively. Also, merged measurements 
could increase the mean passing rate from 1% up to 3.5% in 
some complex cases (Fig.1). 
 
 
 
Fig. 1: The images (Left side) represent the failed points of a 
sample; The images (Right side) depict the average 
volumetric gamma index for prostates, lungs and HN cases in 
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which the outer pie-charts show the results with 3%/3mm and 
the inner pie-charts illustrate results with 2%/2mm.  
 
Conclusion: The results showed that Octavius 4D phantom, 
with 2D-Array seven29, can be an adequate verification 
system both for simple and more complex cases. Additionally, 
the merge capability of the VeriSoft software, which can 
increase spatial resolution, is a useful tool for more complex 
VMAT plans. 
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Purpose or Objective: The aim of this study is to utilize the 
EGSnrc based Monte Carlo code in order to assess the 
EclipseTM (AAA) calculated dose estimation at the Water-
Lung (WL) interfaces when irradiated by 6 MV photon beams 
at 15˚ , 30˚, 45˚ and 60˚ wedge angles and multiple field 
sizes of 5 × 5 cm2, 10 × 10 cm2 and 20 × 20 cm2. 
 
Material and Methods: EGSnrc sub codes are used for Monte 
Carlo dose simulation. BEAMnrc is used to simulate the linear 
accelerator head, whereas DOSXYZnrc is employed to 
perform phantom dose estimation. For simulating dynamic 
wedges the BEAMnrc component module DYNJAWS was 
employed. Phantom geometry includes a 10 cm layer of lung 
(r=0.250 g/cc) sandwiched between 5 cm and 10 cm water 
layers. Doses were calculated in exactly the same geometry 
and same density distribution by Monte Carlo and AAA 
algorithm. The overall dimension of the phantom was 30 cm × 
30 cm × 25 cm. A 5 mm grid size (voxel width) along depth 
was used for calculating PDDs. The nominal source to surface 
distance (SSD) of 100 cm was used in both setups. 
 
Results: The dose perturbation effect was found to be field 
size dependent. It increases with decreasing field size. No 
clear dependence for the wedge angles was observed. No 
dose deviation between AAA and EGSnrc was observed at the 
water→tissue interface. However a lower dose in the lung 
was estimated by AAA. Whereas at the lung→tissue junction 
a highest dose discrepancy was observed by AAA, estimating 
higher dose towards the water layer. 
 
 
 
Conclusion: We have demonstrated the limitation of AAA in 
dose calculation at the water-tissue-water interfaces for four 
wedge angles. There was no significant wedge angle 
dependence on the dose perturbation. However an increase 
in perturbation was observed with decreasing field sizes for 
all angles. 
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Purpose or Objective: Modern dose calculation algorithms 
only model absence of lateral charged particle equilibrium to 
a limited extent. The resulting uncertainties are largest in 
strongly heterogeneous regions, such as the thorax, and will 
potentially increase in deep inspiration breath hold (DIBH) 
due to decreased lung tissue density. 
 
Material and Methods: Ten patients with stage I and ten with 
stage III lung cancer were included. For all patients, a plan in 
free breathing (FB, based on midventilation) and in DIBH 
were made with the clinically used Anysotropic Analytical 
Algorihtm (AAA). Stage I disease was treated stereotactically 
(SBRT) using 3D conformal technique (9-10 fields), 45 Gy in 3 
fractions, prescribed to 95% isodose covering 95% of PTV and 
aiming for 140% dose in the isocenter. Stage III disease was 
treated with VMAT (2 arcs), 66 Gy in 33 fractions, prescribed 
to mean PTV dose. 6 MV energy was used for all plans. 
Calculation grid size was 1 mm for stage I and 2.5 mm for 
stage III. Plans were recalculated in more advanced Acuros 
with same MU as in AAA.  
Plans were compared for target coverage (GTV, CTV, PTV), 
estimated from mean dose, near minimum (D98) and near 
maximum doses (D2), as defined in ICRU 83, and for SBRT 
also for the fraction of PTV covered by prescription dose 
(V45). Organs at risk parameter for stage I was fraction of 
lung receiving more than 13 Gy (V13), and for stage III, mean 
lung dose, lung V5, V20 and V40 and also mean heart dose 
and heart V50. 
 
Results: In DIBH, lung density decreased by median 6% (47.6 
HU) reduction for stage I and 12% (88.5 HU) for stage III.  
In stage III, AAA overestimated mean target doses for FB and 
DIBH GTV and DIBH CTV (by median <0.8 Gy; p<0.05 Wilcoxon 
signed-rank test) and had no impact on D2. AAA 
overestimated D98 by median ~1 Gy for GTV and CTV 
(p<0.05), and more for PTV (by 1.5 Gy and 2.1 Gy, in FB and 
DIBH respectively; p<0.01).  
In stage I, AAA had similar effect on GTV as in stage III. 
However, differences between the two algorithms were 
substantial for PTV and more pronounced in DIBH: AAA 
overestimated all PTV parameters (p<0.01), with largest 
impact on V45 (up to 41.4% in FB and 66.3% in DIBH), while 
mean dose and D98 were overestimated by 2.0 Gy and 2.3 Gy 
in FB and 3.1 Gy and 4.0 Gy in DIBH. These clinically relevant 
differences may be a combination of small targets and large 
dose gradients in the SBRT treated volume.  
Lung and heart dose parameters decreased in DIBH compared 
to FB, but were similar for both algorithms and both disease 
stages (median differences ±0.3% for volumetric parameters 
and ±0.2 Gy for mean doses). More details on actual 
dosimetric parameters are presented in the table. 
